Cizzle Biotechnology: Strategic alliance in China
Cizzle Biotechnology plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung
Cizzle Biotechnology plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung
Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk Interviews to discuss a full commercial development and royalty agreement to develop and market Cizzle Biotechnologies early lung cancer diagnostic
Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced that following the signing of a Memorandum of Understanding with the International Co-Innovation Centre for Advanced Medical Technology and Shenzhen
Cizzle Biotechnology Holdings plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of
Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced that it has executed a Memorandum of Understanding (“MOU”) with the International Co-Innovation Centre for Advanced Medical Technology and Shenzhen
Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced it has executed a research and development agreement to develop a companion diagnostic test for autoimmune disease with St
Cizzle Biotechnology Holdings PLC (LON:CIZ), the UK based diagnostics developer, has announced its results for the six months ended 30th June 2021. Highlights · Completed the acquisition of Cizzle Biotechnology Limited (“CBL”) on
Cizzle Biotechnology plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung
Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced it has executed a royalty sharing agreement with St George Street Capital, the UK-based biomedical charity. As announced on
Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced that it has entered into a new research agreement with the University of York for the development and validation of molecular